>

Invited Speaker



Plenary Lecture

  • Plenary Lecture 1 Checkpoint blockade therapy for melanoma: Combinations to improve outcomes
    Jedd D. WOLCHOK MSKCC USA CV
  • Plenary Lecture 2 Cancer clinical trials and cancer patients care during or after COVID-pandemic
    Giuseppe CURIGLIANO University of Milano Italy CV
  • Plenary Lecture 3 Non-genetic cancer therapy resistance: A cell biologist's perspective
    Joan S BRUGGE Harvard Medical School USA CV
  • Plenary Lecture 4 Drug development:
    The revolution of
    the last 15 years
    Jean-Charles SORIA Amgen Headquarter USA CV


Scientific Symposium

Scientific Symposium 1 Immunotherapy beyond anti-PD1/PDL1 antibody
  • James MOON University of Michigan USA CV
  • Chan KIM CHA Bundang Medical Center Korea CV
  • Melissa L JOHNSON Sarah Cannon Research Institute USA CV
  • Jeffrey S. WEBER NYU School of Medicine USA CV
Scientific Symposium 2 Resistance mechanism of immunotherapy
  • Se-Hoon LEE Samsung Medical Center Korea CV
  • Ross Andrew SOO National University
    of Singapore     Singapore CV
  • Hye Ryun KIM Yonsei Cancer Center Korea CV
  • Yong LU Wake Forest School of Medicine USA CV
Scientific Symposium 3 Clinical application of ctDNA profile
  • Seung-Tae LEE Yonsei University Korea CV
  • Sun-Young KONG National Cancer Center Korea CV
  • Sarat CHANDARLAPATY MSKCC USA CV
Scientific Symposium 4 Targeting endocrine pathway: Breast & prostate
  • Yoon-Sim YAP National Cancer
    Centre Singapore     Singapore CV
  • Bora LIM Baylor College of Medicine USA CV
  • Inkeun PARK Gachon University
    Gil Medical Center     Korea CV
  • Jae Lyun LEE Asan Medical Center Korea CV
Scientific Symposium 5 Recent advances in stomach cancer & GIST
  • Keun-Wook LEE Seoul National University Bundang Hospital Korea CV
  • Kohei SHITARA National Cancer Center Hospital East Japan CV
  • Hyo Song KIM Yonsei University Korea CV
Scientific Symposium 6 Recent advances in NSCLC & SCLC
  • Byoung Chul CHO Yonsei Cancer Center Korea CV
  • Dong-Wan KIM Seoul National University Hospital Korea CV
  • Martin SEBASTIAN University Hospital Frankfurt Germany CV
  • Niels REINMUTH Asklepios Lung Clinic Germany CV
Scientific Symposium 7 Recent advances in Hepatocellular carcinoma/Pancreas-Biliary Ca
  • Ghassan ABOU-ALFA MSKCC USA CV
  • Do-Youn OH Seoul National University Hospital Korea CV
  • Teresa MACARULLA University Hospital of Vall d’Hebron Spain CV
Scientific Symposium 8 Infection and cancer: HBV, HIV, HPV, CMV etc
  • Thomas F. MEYER Max Planck Institute for Infection Biology Germany CV
  • Valerie Chew Suk PENG Translational Immunology Institute (TII) Singapore CV
  • K.C. Allen CHAN The Chinese University of Hong Kong Hong Kong CV
Scientific Symposium 9 Expanding indications of PARP inhibitors
  • Kyung-Hun LEE Seoul National University Hospital Korea CV
  • Mark J O'CONNOR AstraZeneca UK CV
  • Amit M. OZA University of Toronto Canada CV
  • Timothy Anthony YAP The University of Texas MD Anderson Cancer Center USA CV


Joint Symposium

ASCO/KSMO Joint Symposium 1 Integrating next-generation sequencing into clinical practices: Sharing the real-world experiences
  • Lillian L. SIU Princess Margaret
    Cancer Centre     Canada CV
  • Vivek SUBBIAH The University of Texas MD Anderson Cancer Center USA CV
  • Kyong Hwa PARK Korea University Anam Hospital Korea CV
ASCO/KSMO Joint Symposium 2 Ladder of cancer treatment: Precision medicine and palliative care
  • Rodabe N. AMARIA The University of Texas MD Anderson Cancer Center USA CV
  • Yeon Hee PARK Samsung Medical Center Korea CV
  • Ishwaria SUBBIAH The University of Texas MD Anderson Cancer Center USA CV
  • Jung Hye KWON Chungnam National University Sejong Hospital Korea CV
ESMO/KSMO Joint Symposium Updates of IO treatments and Asian subgroup analysis in oncology clinical trials
  • Bhumsuk KEAM Seoul National University Hospital Korea CV
  • Nicolas GIRARD ESMO Officer, Institute Curie France CV
  • Elizabeth SMYTH Cambridge University Hospitals NHS Foundation Trust UK CV
  • Seock-Ah IM Seoul National University Hospital Korea CV
JSMO/KSMO Joint Symposium Biomarker driven clinical trials: Sharing experiences
  • Minkyu JUNG Yonsei Cancer Center Korea CV
  • Yoshiaki NAKAMURA National Cancer Center Hospital East Japan CV
  • Myung-Ju AHN Samsung Medical Center Korea CV
  • Akinobu HAMADA National Cancer Center Research Institute Japan CV
KOSRO/KSMO Joint Symposium De-escalation/escalation of radiotherapy
  • Yong Bae KIM Yonsei Cancer Center Korea CV
  • Sue YOM UCSF USA CV
  • Ken KATO National Cancer Center Hospital Japan CV
  • Sung-Ja AHN Chonnam National University Korea CV
KCSG/KSMO Joint Symposium Conducting phase I clinical trial with targeted therapy/immunotherapy
  • Chan-Young OCK Bang&Ock Consulting Korea CV
  • Jonathan SUN Novartis Oncology China CV
  • Jee Hyun KIM Seoul National University Bundang Hospital Korea CV
KSP/KSMO Joint Symposium Tumor microenvironment and pathology
  • Seung-Yeon YOO Asan Medical Center Korea CV
  • Yoonjin KWAK Seoul National University Hospital Korea CV
  • Mark Borris D. ALDONZA Seoul National University Korea CV
  • Alex SWARBRICK Garvan Institute of Medical Research Australia CV
KSSO/KSMO Joint Symposium Multimodality treatment strategy: Breast surgery in stage IV BC, Neoadj. CTx followed by surgery in LAPC-
  • Jin-Young JANG Seoul National University Hospital Korea CV
  • Changhoon YOO Asan Medical Center Korea CV
  • So Youn JUNG National Cancer Center Korea CV
  • Han Jo KIM Soon Chun Hyang University Hospital Cheonan Korea CV
KSR/KSMO Joint Symposium State-of-the-art oncologic imaging analysis
  • Kyung Won KIM Asan Medical Center Korea CV
  • Ho Yun LEE Samsung Medical Center Korea CV
  • Hongyoon CHOI Seoul National University Hospital Korea CV


Multidisciplinary Oncology Team Education Session

Oncology Multi-Disciplinary Symposium
KOR
Korean Session
Multidisciplinary approach for patients with brain metastasis
  • Se Hyun KIM Seoul National University Bundang Hospital Korea CV
  • Hee Kyung AHN Gachon University Gil Medical Center Korea CV


Multidisciplinary Oncology Team Education Session 1
KOR
Korean Session
Advances in toxicity management
  • Byoung Soo KWON Seoul National University Bundang Hospital Korea CV
  • Hyemi KWON Kangbuk Samsung Hospital Korea CV
  • Chong Won CHOI Seoul National University Bundang Hospital Korea CV
  • Jeong Il YU Samsung Medical Center Korea CV
Multidisciplinary Oncology Team Education Session 2
KOR
Korean Session
Current strategies for maximizing the benefit of immunotherapy
  • Seung-Hoon BEOM Yonsei Cancer Center Korea CV
  • Ji Hyun PARK Konkuk Medical University Hospital Korea CV
  • Hong Jae CHON CHA Bundang Medical Center Korea CV
Multidisciplinary Oncology Team Education Session 3
KOR
Korean Session
Targeted therapy: Clinical effects and resistance
  • Jina YUN Soon Chun Hyang University Hospital Bucheon Korea CV
  • Jae Ho JEONG Asan Medical Center Korea CV
  • Hyewon RYU Chungnam National University Korea CV


Collaborative Symposium

Collaborative Symposium 1 Moving forward to a new paradigm of treatment in advanced gastric cancer
  • Minkyu JUNG Yonsei Cancer Center Korea CV
  • Sook Ryun PARK Asan Medical Center Korea CV
Collaborative Symposium 2 The development of RAS/RAF targeted drugs
  • Sang Joon SHIN Yonsei Cancer Center Korea CV
  • Shiva MALEK Genentech USA CV

Special Symposium

Special Symposium A new path to cardiotoxicity management in the age of precision medicine
  • Yun-Gyoo LEE Kangbuk Samsung Hospital Korea CV
  • Chi Young SHIM Severance Cardiovascular Hospital Korea CV
  • Eun Kyoung KIM Samsung Medical Center Korea CV
  • Peter Y. KIM The University of Texas MD Anderson Cancer Center USA CV

Luncheon Symposium

LUNCHEON SYMPOSIUM 1
MSD
 Front-line therapy for advanced NSCLC immunotherapy and immunotherapy combinations
  • Shirish Madhav GADGEEL University of Michigan USA CV
LUNCHEON SYMPOSIUM 2
ONO Pharma
 Changing the treatment landscape for gastric and GEJ cancer: Nivolumab plus chemotherapy
  • Min-Hee RYU Asan Medical Center Korea CV
LUNCHEON SYMPOSIUM 3
Boryung
 First bevacizumab biosimilar in Korea, ONBEVZI
  • Donghoon SHIN Samsung Bioepis Korea CV
LUNCHEON SYMPOSIUM 4
Roche
 Tecentriq + Avastin: Reigniting progress in the HCC treatment landscape
  • Changhoon YOO Asan Medical Center Korea CV
LUNCHEON SYMPOSIUM 5
astrazeneca
 Paradigm-changing treatment strategy for lung cancer covering early to advanced stages
  • Se-Hoon LEE Samsung Medical Center Korea CV


Satellite Symposium

Satellite Symposium 1
Pfizer
 From science to Real-world data(RWD) with breast cancer patient
  • Yeon Hee PARK Samsung Medical Center Korea CV
  • Matthew James Clifford ELLIS Baylor College of Medicine USA CV
Satellite Symposium 2
Servier
 Management of mPaCa patients: Focused on Liposomal Irinotecan(ONIVYDE)
  • Choong-kun LEE Yonsei Cancer Center Korea CV
Satellite Symposium 3
MSD
 The welcome rain, Pembrolizumab: New hope for MSI-H/dMMR colorectal cancer patients
  • Soohyeon LEE Korea University Anam Hospital Korea CV
Satellite Symposium 4
Eisai
 The evolving HCC treatment landscape: What is the role of LENVIMA
  • Arndt VOGEL Hannover Medical School Germany CV
  • Jaekyung CHEON CHA Bundang Medical Center Korea CV
Satellite Symposium 5
Jeil
 TAS-102, New therapeutic option for patients with CRC / GC
  • Dong-Hoe KOO Kangbuk Samsung Hospital Korea CV
  • Wonyoung CHOI National Cancer Center Korea CV
Satellite Symposium 6
ipsen
 Shifting perception in treatment of advanced renal cell carcinoma
  • Chan KIM CHA Bundang Medical Center Korea CV
  • In-Ho KIM The Catholic University of Korea Seoul St. Mary’s Hospital Korea CV
Satellite Symposium 7
Novartis
 Evolving treatment landscape with CDK 4/6 inhibitors in metastatic breast cancer
  • Kyung-Hun LEE Seoul National University Hospital Korea CV
Satellite Symposium 8
Takeda
 The evolving ALK+ NSCLC paradigm: The future of 1st line and beyond
  • David Ross CAMIDGE UCHealth Lung Cancer Clinic - Anschutz Medical Campus USA CV
Satellite Symposium 9
MSD
 KEYTRUDA® for 1L TNBC – A new hope that blooms in the wild land
  • Rita NANDA UChicago Medicine USA CV
Satellite Symposium 10
innoN
 Optimal treatment strategy in metastatic colorectal cancer
  • Seung-Hoon BEOM Yonsei Cancer Center Korea CV
Satellite Symposium 11
YUHAN
 From clinical trials to practice: New era of EGFRm NSCLC treatment, LECLAZA®
  • Myung-Ju AHN Samsung Medical Center Korea CV
Satellite Symposium 12
Sanofi
 What is being considered for treatment decision for 2nd line mCRC?
  • Soohyeon LEE Korea University Anam Hospital Korea CV
  • Jeong Eun KIM Asan Medical Center Korea CV
Satellite Symposium 13
Amgen
 Optimal bone health management with BTA in bone metastatic solid tumor
  • Jin-Hee AHN Asan Medical Center Korea CV
  • Yoon Ji CHOI Korea University Anam Hospital Korea CV